Literature DB >> 12195626

Serial analysis of Ro/SSA and La/SSB antibody levels and correlation with clinical disease activity in patients with systemic lupus erythematosus.

Adla B Hassan1, Ingrid E Lundberg, David Isenberg, Marie Wahren-Herlenius.   

Abstract

OBJECTIVE: To investigate the temporal correlation between anti-Ro/SSA and anti-La/SSB antibody levels and compare them with variation in clinical disease activity in patients with systemic lupus erythematosus (SLE).
METHODS: Sequential serum samples collected over 18-44 months from 18 anti-Ro/SSA positive patients with systemic lupus erythematosus were analysed by ELISA with recombinant Ro60, Ro52 and La antigens. Disease activity was assessed by the BILAG index.
RESULTS: Limited antibody level variation over time was found in most patients, but a subset displayed more changes and a co-variation between the levels of separate specificities was found in 40% of patients. In two patients antibody levels fluctuated with the global score. Antibodies also correlated with separate organ/systems involvement in individual patients.
CONCLUSION: The Ro60, Ro52 and La antibody profile is fixed at an early stage of disease and in most patients hardly changes. Patients with fluctuating levels tend to have a co-ordinated expression of these autoantibodies.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12195626

Source DB:  PubMed          Journal:  Scand J Rheumatol        ISSN: 0300-9742            Impact factor:   3.641


  14 in total

1.  Accuracy of semiquantitative immunoenzymatic methods in quantitation of anti-topoisomerase I (Scl-70) antibodies.

Authors:  D Villalta; N Bizzaro; S Platzgummer; A Antico; M Tampoia; L Camogliano; D Bassetti; M Pradella; A Piazza; F Manoni; R Tozzoli; E Tonutti
Journal:  Clin Rheumatol       Date:  2004-12-10       Impact factor: 2.980

2.  Longitudinal anti-nuclear antibody (ANA) seroconversion in systemic lupus erythematosus: a prospective study of Swedish cases with recent-onset disease.

Authors:  M Frodlund; J Wetterö; C Dahle; Ö Dahlström; T Skogh; J Rönnelid; C Sjöwall
Journal:  Clin Exp Immunol       Date:  2019-12-19       Impact factor: 4.330

3.  A study on the association of autoantibodies, chemokine, and its receptor with disease activity in systemic lupus erythematosus in North Indian population.

Authors:  Leishangthem Bidyalaxmi Devi; Archana Bhatnagar; Ajay Wanchu; Aman Sharma
Journal:  Rheumatol Int       Date:  2013-07-06       Impact factor: 2.631

4.  Expression of Toll‑like receptors 3 and 9 in Egyptian systemic lupus erythematosus patients.

Authors:  A S Nasr; S M Fawzy; T A Gheita; E El-Khateeb
Journal:  Z Rheumatol       Date:  2016-06       Impact factor: 1.372

5.  Cytokine induction by circulating immune complexes and signs of in-vivo complement activation in systemic lupus erythematosus are associated with the occurrence of anti-Sjögren's syndrome A antibodies.

Authors:  L Mathsson; E Ahlin; C Sjöwall; T Skogh; J Rönnelid
Journal:  Clin Exp Immunol       Date:  2007-03       Impact factor: 4.330

6.  Autoantibodies from mice exposed to Libby amphibole asbestos bind SSA/Ro52-enriched apoptotic blebs of murine macrophages.

Authors:  David J Blake; Scott A Wetzel; Jean C Pfau
Journal:  Toxicology       Date:  2008-01-19       Impact factor: 4.221

7.  Antibodies to amino acid 200-239 (p200) of Ro52 as serological markers for the risk of developing congenital heart block.

Authors:  L Strandberg; O Winqvist; S-E Sonesson; S Mohseni; S Salomonsson; K Bremme; J P Buyon; H Julkunen; M Wahren-Herlenius
Journal:  Clin Exp Immunol       Date:  2008-08-22       Impact factor: 4.330

Review 8.  Anti-DNA antibodies--quintessential biomarkers of SLE.

Authors:  David S Pisetsky
Journal:  Nat Rev Rheumatol       Date:  2015-11-19       Impact factor: 20.543

Review 9.  Clinical and pathological roles of Ro/SSA autoantibody system.

Authors:  Ryusuke Yoshimi; Atsuhisa Ueda; Keiko Ozato; Yoshiaki Ishigatsubo
Journal:  Clin Dev Immunol       Date:  2012-12-06

Review 10.  Serology of Lupus Erythematosus: Correlation between Immunopathological Features and Clinical Aspects.

Authors:  Emanuele Cozzani; Massimo Drosera; Giulia Gasparini; Aurora Parodi
Journal:  Autoimmune Dis       Date:  2014-02-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.